Efficacy News and Research

RSS

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

4 Feb 2014

Innovation Center's methods under the microscope

The idea seemed transformative. The Affordable Care Act would fund a new research outfit evocatively named the Innovation Center to discover how to most effectively deliver health care, with $10 billion to spend over a decade.

4 Feb 2014

Researchers discover genetic function that helps "tumor suppressor" genes to prevent cancer

Researchers at Oregon State University have discovered a genetic function that helps one of the most important "tumor suppressor" genes to do its job and prevent cancer.

4 Feb 2014

Incontinence prophylaxis shows potential in pelvic organ prolapse

Research from Taiwan suggests that combining trocar-guided transvaginal mesh surgery with a midurethral sling in the treatment of women with advanced pelvic organ prolapse could be an effective way to manage associated stress urinary incontinence.

3 Feb 2014

First Edition: February 3, 2014

Today's headlines include a range of stories about how the health law is working in different locations across the country.

3 Feb 2014

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has executed two agreements; with Ildong Pharmaceuticals Co Ltd, Korea and Ergomed Clinical Research Ltd, UK to support further clinical studies of Lorediplon in patients with insomnia.

3 Feb 2014

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

3 Feb 2014

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

EORTC study evaluates health-related quality of life assessment in small-cell lung cancer

An EORTC study published in Lancet Oncology found that health-related quality of life assessment in small-cell lung cancer randomized clinical trials provides relevant added information in studies where the treatment arms do not differ in terms of efficacy.

29 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Seward Ltd., manufacturers of the world leading range of Stomacher paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Efficacy News and Research

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Innovation Center's methods under the microscope

Researchers discover genetic function that helps "tumor suppressor" genes to prevent cancer

Incontinence prophylaxis shows potential in pelvic organ prolapse

First Edition: February 3, 2014

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

New study reveals way to combat drug-resistant tumors

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

EORTC study evaluates health-related quality of life assessment in small-cell lung cancer

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

S. pneumoniae predicts acute sinusitis microbial response

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News